PIK3CA and neoplasm: When tested in vivo, however, the combination of talazoparib + BKM-120 delayed tumor growth to a significantly greater degree than either talazoparib or BKM-120 alone, supporting further investigation of a PARP-PI3K inhibitor combination in SCLC clinical trials.